• 2'3'-cGAMP and the Next STING Frontier

  2026-10-06

  The next phase of cGAS-STING research will connect innate immune signaling with metabolic state. This thought-leadership analysis examines how 2'3'-cGAMP can serve as a defined STING-proximal research tool, while the 2025 D2HG biosensor study opens new questions about immune–metabolic feedback, translational biomarkers, and the limits of current evidence.

• GLP-1 (9-36) Amide: Evidence and Limits

  2026-10-06

  This source-grounded overview explains what GLP-1 (9-36) amide can and cannot establish in GLP-1 receptor signaling research. It separates supplier descriptions from findings in a 2019 study of glucagon–GLP-1 receptor crosstalk, while addressing evidence quality, interpretation, scope, and limitations.

• BIIE 0246 and the Adipose-Neural Axis

  2026-10-05

  BIIE 0246 is a selective neuropeptide Y Y2 receptor antagonist that can help clarify receptor-subtype logic in neuropeptide signaling. This article interprets its research value alongside new evidence linking adipose-neural communication to cardiac arrhythmia, while defining what the findings do—and do not—establish.

• PTH (1-34) Peptide: A Kidney Modeling Lens

  2026-10-05

  Parathyroid hormone (1-34) (human) offers a focused way to interrogate PTH/PTHrP receptor signaling across bone and kidney research. This article develops an evidence-based framework for interpreting the peptide alongside spatial kidney assembloids without overstating what either model can establish.

• GLP-1 (9-36) Amide: Evidence and Research Context

  2026-10-04

  GLP-1 (9-36) amide is marketed as a glucagon-like peptide-1 receptor antagonist for research, but the supplied primary study directly evaluates exendin(9-39) and related ligands rather than GLP-1 (9-36) amide itself. This overview places the peptide in the broader context of GLP-1 receptor signaling research, explains what the published evidence shows about receptor cross-reactivity, and defines the limits of translating in vitro cAMP findings to metabolic or therapeutic conclusions.

• 2'3'-cGAMP: From STING Signal to Metabolic Readout

  2026-10-03

  Explore how 2'3'-cGAMP can serve not only as a STING pathway stimulus but also as a mechanistic anchor for studying immune–metabolic signaling. This evidence-focused analysis connects cGAS-STING activation with D2HG biosensing while defining the limits of current evidence.

• 2-Deoxy-D-glucose: A Metabolic Assay Compass

  2026-10-02

  2-Deoxy-D-glucose is more than a glycolysis inhibitor: it is a causal probe for testing how metabolic state shapes cell phenotype. This article connects 2-DG assay design with macrophage metabolic reprogramming, cancer metabolism, and interpretation of translational experiments.

• Cyclo (-RGDfC) Workflow for Integrin Assays

  2026-10-01

  Cyclo (-RGDfC) supports practical αvβ3-focused workflows spanning cell adhesion, migration, angiogenesis research, and targeted delivery. This guide combines product-handling advice with assay controls inspired by a canine osteosarcoma viability study, helping researchers distinguish receptor-mediated effects from general cytotoxicity.

• Methyl-β-cyclodextrin: Practical Lab Guide

  2026-10-01

  Methyl-β-cyclodextrin (SKU C6939) is a biochemical reagent for membrane cholesterol extraction and controlled studies of membrane organization. It is intended for research workflows only; working concentrations, exposure conditions, and cell compatibility must be established for each assay rather than inferred from the product specification.

• Indazole/Indole Glucagon Receptor Antagonists

  2026-09-30

  Lin and colleagues reported a novel indazole- and indole-based series of glucagon receptor antagonists designed from the earlier MK-0893 scaffold, combining systematic SAR with promising in vitro, pharmacokinetic, and acute in vivo activity. The study also illustrates how HOBt-supported amide bond formation can be integrated into small-molecule medicinal chemistry routes.

• Z-YVAD-FMK: A Practical Caspase-1 Inhibitor Guide

  2026-09-30

  Z-YVAD-FMK enables pathway-resolved studies of caspase-1 activity, inflammatory cytokine release, apoptosis, and pyroptosis rather than relying on viability measurements alone. This guide translates product characteristics and a lung epithelial bystander-death study into practical assay design, controls, troubleshooting, and interpretation strategies.

• Parathyroid hormone (1-34) (human): Research Guide

  2026-09-29

  Parathyroid hormone (1-34) (human) is a bioactive PTH (1-34) peptide fragment for receptor-signaling, bone metabolism, and calcium-homeostasis studies. Its defined sequence, cAMP potency, solubility profile, and rat bone-mass findings support controlled use in osteoporosis model and kidney-disease research, but the reagent is not a clinical treatment.

• Cyclo (-RGDfC) for Spatial Integrin Assays

  2026-09-29

  Discover how Cyclo (-RGDfC) and c(RGDfC) can support spatially resolved integrin assays by combining αvβ3 recognition with open-platform hydrogel printing. This article translates recent OP-DLP advances into practical tumor targeting peptide workflows while separating established evidence from experimental recommendations.

• Adipose–Neural Signaling in Cardiac Arrhythmia

  2026-09-28

  Fan et al. developed a stem cell-based coculture model showing that epicardial adipocytes can activate sympathetic neurons through leptin, increase NPY release, and promote cardiomyocyte arrhythmia through Y1R, NCX, and CaMKII. The study connects this mechanism with increased epicardial adipose tissue thickness and circulating leptin and NPY in patients with atrial fibrillation, while also defining important boundaries for future Y2R-focused experiments.

• Indazole and Indole Glucagon Receptor Antagonists

  2026-09-28

  Lin and colleagues describe indazole- and indole-based glucagon receptor antagonists derived from the MK-0893 design concept, with structure–activity studies and preclinical evaluation identifying orally active compound 16d. The findings support further investigation of this chemical series, while the evidence remains limited to in vitro and acute mouse studies rather than demonstrating clinical benefit.

8424 records 1/562 page Next 12345 下5页 Last page